Galectin-3 is associated with severe heart failure and death: A hospital-based study in Chinese patients

Area of Science:

• Cardiology
• Immunology
• Biochemistry

Background:

• Heart failure (HF) is linked to increased pro-inflammatory cytokines, but the role of galectins in HF pathogenesis remains unclear.
• Galectins are carbohydrate-binding proteins involved in diverse physiological processes.
• Understanding galectin involvement in HF is crucial for developing new diagnostic and therapeutic strategies.

Purpose of the Study:

• To investigate the association between galectin levels (Gal-1, Gal-3, Gal-9) and heart failure (HF).
• To explore the correlation of galectins with inflammatory cytokines and clinical severity in HF patients.
• To evaluate galectin-3 as a potential biomarker for HF diagnosis, severity, and prognosis.

Main Methods:

• A case-control study involving 136 HF patients and 125 healthy Chinese controls.
• Quantification of galectins (Gal-1, 3, 9) and cytokines (IFN-γ, IL-17A, IL-4, TGF-β) using ELISA.
• Statistical analysis including correlation, ROC curve analysis, and a two-year mortality follow-up.

Main Results:

• HF patients exhibited significantly higher levels of galectin-1 and galectin-3 compared to controls.
• Elevated galectin-3 levels correlated positively with pro-inflammatory cytokines (IFN-γ, IL-17A) and inversely with TGF-β.
• Galectin-3 demonstrated potential as a biomarker for HF diagnosis and severity, and elevated levels predicted HF-related mortality over two years.

Conclusions:

• Galectin-3 is associated with heart failure, clinical severity, and mortality, potentially through the induction of pro-inflammatory cytokines.
• Galectin-3 emerges as a promising biomarker for diagnosing HF and assessing clinical severity.
• Further research into galectin-3's role could lead to novel therapeutic targets for heart failure.